A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197) in Children With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2017 Results published in the Pediatric Blood and Cancer Journal.
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.